Summary
25.29 0.05(0.20%)11/04/2024
Smith & Nephew plc (SNN)
Smith & Nephew plc (SNN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.22 | -12.34 | -15.67 | -14.05 | 2.18 | 4.59 | -36.91 | 454.04 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 25.29 | |
| Open | 25.10 | |
| High | 25.39 | |
| Low | 25.10 | |
| Volume | 664,599 | |
| Change | 0.06 | |
| Change % | 0.22 | |
| Avg Volume (20 Days) | 800,294 | |
| Volume/Avg Volume (20 Days) Ratio | 0.83 | |
| 52 Week Range | 23.65 - 31.72 | |
| Price vs 52 Week High | -20.27% | |
| Price vs 52 Week Low | 6.93% | |
| Range | 0.76 | |
| Gap Up/Down | -0.75 | |
Fundamentals | ||
| Market Capitalization (Mln) | 13,428 | |
| EBIDTA | 1,116,999,936 | |
| PE Ratio | 42.0333 | |
| PEG Ratio | 0.4494 | |
| WallStreet Target Price | 30.50 | |
| Book Value | 5.9840 | |
| Earnings Per Share | 0.6000 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 1.2500 | |
| EPS Estimate Next Year | 1.5100 | |
| Diluted EPS (TTM) | 0.6000 | |
| Revenues | ||
| Profit Marging | 0.0474 | |
| Operating Marging (TTM) | 0.1446 | |
| Return on asset (TTM) | 0.0427 | |
| Return on equity (TTM) | 0.0502 | |
| Revenue TTM | 5,549,000,192 | |
| Revenue per share TTM | 2.5484 | |
| Quarterly Revenue Growth (YOY) | 0.0760 | |
| Quarterly Earnings Growth (YOY) | 0.9830 | |
| Gross Profit (TTM) | 3,695,000,000 | |
| Dividends | ||
| Dividend Share | 0.3750 | |
| Dividend Yield | 0.0297 | |
| Valuations | ||
| Trailing PE | 42.0333 | |
| Forward PE | 12.0773 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.9918 | |
| Revenue Enterprise Value | 2.4027 | |
| EBITDA Enterprise Value | 13.9462 | |
| Shares | ||
| Shares Outstanding | 437,172,992 | |
| Shares Float | 862,752,855 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.03 | |
| Institutions (%) | 7.50 | |
11/02 08:57 EST - seekingalpha.com
Smith & Nephew plc (SNN) Q3 2024 Earnings Conference Call Transcript
Smith & Nephew plc (NYSE:SNN ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 AM ET Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Participants Jack Reynolds-Clark - RBC Capital Management David Adlington - J.P. Morgan Hassan Al-Wakeel - Barclays Robert Davies - Morgan Stanley Richard Felton - Goldman Sachs Graham Doyle - UBS Lisa Clive - Bernstein Julien Dormois - Jefferies Deepak Nath Good morning, and welcome to the Smith & Nephew third quarter trading update.
Smith & Nephew plc (SNN) Q3 2024 Earnings Conference Call Transcript
Smith & Nephew plc (NYSE:SNN ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 AM ET Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Participants Jack Reynolds-Clark - RBC Capital Management David Adlington - J.P. Morgan Hassan Al-Wakeel - Barclays Robert Davies - Morgan Stanley Richard Felton - Goldman Sachs Graham Doyle - UBS Lisa Clive - Bernstein Julien Dormois - Jefferies Deepak Nath Good morning, and welcome to the Smith & Nephew third quarter trading update.
10/31 04:16 EST - proactiveinvestors.co.uk
Smith+Nephew slashes revenue outlook as China headwinds emerge
British medical equipment manufacturer Smith & Nephew PLC (LSE:SN) slashed its full-year revenue outlook to account for a downturn in demand and pricing pressures in the Chinese market. The FTSE 100-listed group now expects full-year revenue growth of 4.5%, compared to 5-6% growth previously expected.
Smith+Nephew slashes revenue outlook as China headwinds emerge
British medical equipment manufacturer Smith & Nephew PLC (LSE:SN) slashed its full-year revenue outlook to account for a downturn in demand and pricing pressures in the Chinese market. The FTSE 100-listed group now expects full-year revenue growth of 4.5%, compared to 5-6% growth previously expected.
10/31 03:17 EST - reuters.com
Smith & Nephew slashes annual revenue forecast on weak China
British medical equipment maker Smith & Nephew cut its annual underlying revenue growth forecast on Thursday to 4.5% from the previous outlook range of 5% to 6%, primarily hurt by challenges in its surgical businesses in China.
Smith & Nephew slashes annual revenue forecast on weak China
British medical equipment maker Smith & Nephew cut its annual underlying revenue growth forecast on Thursday to 4.5% from the previous outlook range of 5% to 6%, primarily hurt by challenges in its surgical businesses in China.
10/16 09:00 EST - globenewswire.com
RENASYS™ EDGE Negative Pressure Wound Therapy System wins Red Dot Award for Design
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, is proud to announce that its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System has won the Red Dot Award for Design Concept 2024 in the Medical Devices and Technology Category , recognizing its intuitive pairing of NPWT housed in a patient-friendly design.
RENASYS™ EDGE Negative Pressure Wound Therapy System wins Red Dot Award for Design
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, is proud to announce that its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System has won the Red Dot Award for Design Concept 2024 in the Medical Devices and Technology Category , recognizing its intuitive pairing of NPWT housed in a patient-friendly design.
10/15 13:36 EST - zacks.com
SNN Stock May Gain Following the Co-Marketing Deal With JointVue
Smith & Nephew and JointVue announce a co-marketing agreement for the latter's OrthoSonic 3D Surgery Planning Technology.
SNN Stock May Gain Following the Co-Marketing Deal With JointVue
Smith & Nephew and JointVue announce a co-marketing agreement for the latter's OrthoSonic 3D Surgery Planning Technology.
10/11 10:16 EST - zacks.com
SNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System
Smith & Nephew introduces the LEGION Hinged Knee System with OXINIUM Technology, elevating knee revision surgery through innovation.
SNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System
Smith & Nephew introduces the LEGION Hinged Knee System with OXINIUM Technology, elevating knee revision surgery through innovation.
10/09 08:00 EST - globenewswire.com
Smith+Nephew partners with JointVue™ for Ultrasound preoperative planning in robotics-assisted surgery
Patented technology further personalizes total knee arthroplasty for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed a co-marketing agreement with JointVue for its patented OrthoSonic™ 3D Surgery Planning Technology – the only ultrasound device currently on the market to deliver 3D preoperative planning. JointVue's technology allows surgeons using Smith+Nephew's CORI◊ Surgical System for robotic-assisted knee arthroplasty to create a personalized surgical plan, which may provide opportunities to improve patient satisfaction and operating room efficiency.
Smith+Nephew partners with JointVue™ for Ultrasound preoperative planning in robotics-assisted surgery
Patented technology further personalizes total knee arthroplasty for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed a co-marketing agreement with JointVue for its patented OrthoSonic™ 3D Surgery Planning Technology – the only ultrasound device currently on the market to deliver 3D preoperative planning. JointVue's technology allows surgeons using Smith+Nephew's CORI◊ Surgical System for robotic-assisted knee arthroplasty to create a personalized surgical plan, which may provide opportunities to improve patient satisfaction and operating room efficiency.
09/20 12:51 EST - zacks.com
SNN Stock Rises on the Completion of First Case With CATALYSTEM System
Smith & Nephew announces the completion of the first case using the CATALYSTEM Primary Hip System.
SNN Stock Rises on the Completion of First Case With CATALYSTEM System
Smith & Nephew announces the completion of the first case using the CATALYSTEM Primary Hip System.
09/18 12:40 EST - youtube.com
This stock is 'boring' but has 'fantastic' risk-reward: Scharf
Eric Lynch from Scharf Investments explains why he likes the non-tech and utilities sectors.
This stock is 'boring' but has 'fantastic' risk-reward: Scharf
Eric Lynch from Scharf Investments explains why he likes the non-tech and utilities sectors.
09/18 10:00 EST - globenewswire.com
First cases using Smith+Nephew's new CATALYSTEM™ Primary Hip System completed; surgeons hail precision, efficiency and reproducibility
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces promising surgeon feedback from the first completed cases utilizing its new CATALYSTEM Primary Hip System. Designed to address the evolving demands of primary hip surgery - including the increased adoption of anterior approach procedures – the CATALYSTEM Primary Hip System features a triple-taper stem design with uniform proximal loading.1  The reduced distal stem geometry and shorter lengths are ideal for anterior approach but suitable for all approaches.2
First cases using Smith+Nephew's new CATALYSTEM™ Primary Hip System completed; surgeons hail precision, efficiency and reproducibility
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces promising surgeon feedback from the first completed cases utilizing its new CATALYSTEM Primary Hip System. Designed to address the evolving demands of primary hip surgery - including the increased adoption of anterior approach procedures – the CATALYSTEM Primary Hip System features a triple-taper stem design with uniform proximal loading.1  The reduced distal stem geometry and shorter lengths are ideal for anterior approach but suitable for all approaches.2
09/13 13:26 EST - zacks.com
SNN Stock Declines Despite the Launch of Its Patient-Matched Guides
Smith & Nephew announces the launch of its TOTAL ANKLE Patient-Matched Guides to plan and perform total ankle replacement procedures.
SNN Stock Declines Despite the Launch of Its Patient-Matched Guides
Smith & Nephew announces the launch of its TOTAL ANKLE Patient-Matched Guides to plan and perform total ankle replacement procedures.
09/10 10:00 EST - globenewswire.com
Smith+Nephew brings pre-operative planning and accuracy to total ankle replacement with new TOTAL ANKLE Patient-Matched Guides
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its TOTAL ANKLE Patient-Matched Guides, giving surgeons a predictable and efficient option to help plan and perform total ankle replacement (TAR) procedures. Engineered using 3D Systems' VSP® surgical planning workflows, all-in-one TOTAL ANKLE Patient-Matched Guides are designed to achieve a precise patient fit using fluoroscopic alignment cues and efficient instrumentation, and provide accuracy to plan.1-8
Smith+Nephew brings pre-operative planning and accuracy to total ankle replacement with new TOTAL ANKLE Patient-Matched Guides
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its TOTAL ANKLE Patient-Matched Guides, giving surgeons a predictable and efficient option to help plan and perform total ankle replacement (TAR) procedures. Engineered using 3D Systems' VSP® surgical planning workflows, all-in-one TOTAL ANKLE Patient-Matched Guides are designed to achieve a precise patient fit using fluoroscopic alignment cues and efficient instrumentation, and provide accuracy to plan.1-8
08/21 20:30 EST - seekingalpha.com
Smith & Nephew Delivering On Its Turnaround Promise
The Street has taken notice of Smith & Nephew's turnaround progress, with better than expected revenue and margin results driving share price outperformance. While the ortho business has continued to grow, SNN has continued to lose share in major joints and this is the biggest item on management's to-do list now. Management has identified additional savings opportunities that will help boost margins further, and coupled with improved sales execution, could drive EBITDA to 30% over the next five years.
Smith & Nephew Delivering On Its Turnaround Promise
The Street has taken notice of Smith & Nephew's turnaround progress, with better than expected revenue and margin results driving share price outperformance. While the ortho business has continued to grow, SNN has continued to lose share in major joints and this is the biggest item on management's to-do list now. Management has identified additional savings opportunities that will help boost margins further, and coupled with improved sales execution, could drive EBITDA to 30% over the next five years.
08/12 12:25 EST - zacks.com
Smith & Nephew (SNN) Partners InfuSystem for Renasys Edge
Smith & Nephew (SNN) inks a three-year agreement with InfuSystem (INFU) to distribute its RENASYS EDGE negative pressure wound therapy system.
Smith & Nephew (SNN) Partners InfuSystem for Renasys Edge
Smith & Nephew (SNN) inks a three-year agreement with InfuSystem (INFU) to distribute its RENASYS EDGE negative pressure wound therapy system.
08/07 14:12 EST - zacks.com
Smith & Nephew (SNN), HOPCo to Enhance Musculoskeletal Care
Smith & Nephew (SNN) announces a collaboration with HOPCo to focus on enhancing solutions for ASC customers, physicians, and patients through the latter's digital health and analytics platforms.
Smith & Nephew (SNN), HOPCo to Enhance Musculoskeletal Care
Smith & Nephew (SNN) announces a collaboration with HOPCo to focus on enhancing solutions for ASC customers, physicians, and patients through the latter's digital health and analytics platforms.
08/01 03:58 EST - proactiveinvestors.co.uk
Smith & Nephew jumps on progress with turnaround of hip and knee arm
Shares in Smith & Nephew PLC (LSE:SN) sprang 7.7% higher as the replacement hip and knee specialist reported some encouraging elements in its interim results. Overall, the numbers for the first half ended 29 June were in line with forecasts, including revenue grew 3.4% to $2.8 billion, or 4.3% on an underlying basis versus consensus forecasts of 4.2%.
Smith & Nephew jumps on progress with turnaround of hip and knee arm
Shares in Smith & Nephew PLC (LSE:SN) sprang 7.7% higher as the replacement hip and knee specialist reported some encouraging elements in its interim results. Overall, the numbers for the first half ended 29 June were in line with forecasts, including revenue grew 3.4% to $2.8 billion, or 4.3% on an underlying basis versus consensus forecasts of 4.2%.
08/01 03:28 EST - reuters.com
Smith & Nephew shares rise as profit beats market forecast
Smith & Nephew's shares rose 9% on Thursday after the British medical equipment maker's half-year profit beat market forecast, helped by a strong performance in its orthopaedics segment.
Smith & Nephew shares rise as profit beats market forecast
Smith & Nephew's shares rose 9% on Thursday after the British medical equipment maker's half-year profit beat market forecast, helped by a strong performance in its orthopaedics segment.
07/24 10:46 EST - zacks.com
Should Value Investors Buy Smith & Nephew SNATS (SNN) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Smith & Nephew SNATS (SNN) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
07/17 13:30 EST - zacks.com
Smith & Nephew's (SNN) CATALYSTEM System Gets FDA Clearance
Smith & Nephew (SNN) announces the receipt of FDA clearance for its new CATALYSTEM Primary Hip System, which is intended to address the demands of primary hip surgery.
Smith & Nephew's (SNN) CATALYSTEM System Gets FDA Clearance
Smith & Nephew (SNN) announces the receipt of FDA clearance for its new CATALYSTEM Primary Hip System, which is intended to address the demands of primary hip surgery.
07/13 09:20 EST - cnbc.com
Activist Cevian has a stake in medical device company Smith & Nephew. How it may help improve margins
British company Smith & Nephew is already a global leader in medical tech. Cevian could help it boost its profitability.
Activist Cevian has a stake in medical device company Smith & Nephew. How it may help improve margins
British company Smith & Nephew is already a global leader in medical tech. Cevian could help it boost its profitability.